Brief: Bayer’s Ambelvist Receives FDA Approval For Contrast-Enhanced Mri To Detect And Visualize Lesions With Abnormal Vascularity In The Central Nervous System And Non-Cns Body Regions
15/06/2026 07:32
BRIEF-Bayer’s Ambelvist Receives FDA Approval For Contrast-Enhanced Mri To Detect And Visualize Lesions With Abnormal Vascularity In The Central Nervous System And Non-Cns Body Regions June 15 (Reuters) - BAYER AG BAYGn.DE:
BAYER’S AMBELVIST® (GADOQUATRANE) RECEIVES FDA APPROVAL FOR CONTRAST-ENHANCED MRI TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM AND NON-CNS BODY REGIONS
Source text: ID:nBwkssg3a
Further company coverage: [BAYGn.DE]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)